Clinical trials
Metastatic Cervical Cancer clinical trials
Below are recruiting metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 360 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07472153RecruitingPhase 2/Phase 3
Immunotherapy plus chemo for advanced cervical cancer
This trial tests adding immunotherapy drugs (PD-1 or PD-L1 inhibitors) to standard chemotherapy, with or without bevacizumab, for people with cervical cancer that has spread, persisted, or come back after treatment. The goal is to see which combination works better.
Minsk, LesnoyAges 18–75 - NCT07645625RecruitingPhase 4
Pembrolizumab outcomes study in cervical cancer
This study tracks how well pembrolizumab works in people with cervical cancer that has come back, spread, or not gone away. It includes two groups: one for those currently on or starting the drug, and one for those who stop early due to a good response or side effects.
AmsterdamAges 18 years+ - NCT07593820RecruitingPhase 1
CAR-T Cell Study for Advanced HER2-Positive Cancers
This early-stage trial tests a new type of immune cell therapy called CAR-T cells, which are designed to recognize and attack cancer cells that have a protein called HER2. The cells are made from your own immune cells, trained in the laboratory, and given back to you. The study evaluates how safe the treatment is and whether it can shrink tumors.
Barcelona, CataloniaAges 18 years+ - NCT07608848RecruitingEarly Phase 1
Imaging study of new cancer-targeting radioactive drugs
This study tests two new radioactive drugs designed to find and image advanced breast or prostate cancer. The drugs use special imaging scans (PET and SPECT) to locate tumors and may help guide future treatment decisions.
Perth, Western AustraliaAges 18 years+ - NCT06755515Enrolling by invitationPhase 2/Phase 3
Rulonilimab + Chemo for Advanced Cervical Cancer
This trial tests a new drug called Rulonilimab combined with chemotherapy, with or without bevacizumab, as the first treatment for cervical cancer that has spread or come back. It’s for people whose tumors have a specific marker (PD-L1) and who haven’t had other treatments for advanced disease.
Linyi, ShandongAges 18 years+ - NCT07168200RecruitingPhase 3
Study of Adebrelimab with Chemoradiation for Advanced Cervical Cancer
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemoradiation helps treat locally advanced cervical cancer better than chemoradiation alone.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT06394297Recruiting
Virtual Brachytherapy Planning for Advanced Cervical Cancer
This study tests a new way to plan a type of radiation called brachytherapy for advanced cervical cancer. It uses virtual images to see if this method can treat the tumor just as well while being safer.
LisbonAges 18 years+ - NCT06630611RecruitingPhase 2
A new immune cell therapy for melanoma, lung, and cervical cancer
This trial tests a new way to boost your immune cells after they are collected from your tumor and grown in a lab. Instead of high-dose IL-2, you would get a modified version called ANV419, which may have fewer side effects.
BarcelonaAges 18 years+ - NCT06784921Recruiting
Study of sacituzumab govitecan for HER2-negative breast cancer
This study looks at how well a drug called sacituzumab govitecan works and how safe it is for people with a certain type of breast cancer that has spread (HER2-negative metastatic breast cancer). It aims to understand real-world results for patients in China.
Hangzhou, ZhejiangAges 18–75 - NCT06873763RecruitingPhase 1/Phase 2
Nelmastobart with chemo for advanced colorectal cancer
This trial tests a new immunotherapy drug, nelmastobart, combined with two standard chemotherapy drugs (trifluridine/tipiracil and bevacizumab) for people with advanced colorectal cancer that hasn't responded to other treatments. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT07198724RecruitingPhase 1/Phase 2
A study of elacestrant plus Enhertu for advanced breast cancer
This trial tests a new combination of two targeted drugs (elacestrant and Enhertu) for people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultra-low) that did not respond to standard treatments like CDK4/6 inhibitors. The goal is to see if this combination works better than current options.
Boston, MassachusettsAges 18 years+ - NCT07597083Recruiting
Pelvic Floor Training for Sexual Function After Cervical Cancer
This study tests whether biofeedback-assisted pelvic floor rehabilitation—a guided exercise program with real-time feedback—can improve sexual function in women who experienced sexual difficulties after radiation treatment for cervical cancer. The goal is to help restore comfort and satisfaction in intimate life.
Banī SuwayfAges 30–60 - NCT05205200RecruitingPhase 2
Immune therapy for HR-positive, HER2-negative metastatic breast cancer
This Phase 2 trial studies an immune-based treatment for women with HR-positive and HER2-negative breast cancer that has spread or returned and can’t be cured with local treatment alone. The goal is to see whether the therapy can shrink tumors and improve disease control with acceptable safety.
ShanghaiAges 18–75 - NCT06583070Recruiting
SABR plus targeted therapy and immunotherapy for advanced kidney cancer
This trial tests combining a precise type of radiation (SABR) with standard targeted therapy and immunotherapy drugs for kidney cancer that has come back or spread. The goal is to see if adding radiation improves outcomes.
Beijing, Beijing MunicipalityAges 18–85 - NCT06951997RecruitingPhase 2
First treatment for metastatic pancreatic cancer using three drugs
This trial tests a new combination of three drugs (QL1706, chidamide, and AG) as the very first treatment for people with metastatic pancreatic cancer. The goal is to see if this combination is safe and effective, and it may offer a new option for those who have not had any prior therapy.
TianjinAges 18–75 - NCT06959589Enrolling by invitationPhase 2
Combination therapy for KRAS G12C mutated colorectal cancer
This trial tests a new drug combination (IBI351, cetuximab, and FOLFIRI) as first treatment or as a second treatment after standard chemotherapy for people with KRAS G12C mutated colorectal cancer that has spread. The goal is to see if it works well and is safe.
Hangzhou, ZhejiangAges 18–75 - NCT06752811RecruitingPhase 3
Testing a new paclitaxel formula for advanced pancreatic cancer
This trial tests a new form of the chemotherapy drug paclitaxel (called polymeric micellar paclitaxel) for people with pancreatic cancer that has spread to other parts of the body (metastatic). It's for those who haven't had any prior treatment for their metastatic cancer, and aims to see if this drug can help control the cancer.
Nanjing, JiangsuAges 18–75 - NCT06282445RecruitingPhase 2
Combination therapy for first-line metastatic colorectal cancer
This trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy plus bevacizumab can help people with a specific type of metastatic colorectal cancer that cannot be removed by surgery. It is for patients whose tumors are microsatellite stable (MSS) or have normal mismatch repair (pMMR).
Jinhua, ZhejiangAges 18–75 - NCT04263298RecruitingPhase 3
Fulvestrant or capecitabine after chemo for metastatic breast cancer
This Phase 3 trial compares two medicines—fulvestrant versus capecitabine—as “maintenance” treatment after your first chemo helps control metastatic breast cancer. It aims to see which one helps people live longer with better disease control.
Guangzhou, GuangdongAges 18–75 - NCT04689347RecruitingPhase 1/Phase 2
New chemotherapy and targeted drug for a specific colon cancer type
This trial tests a combination of chemotherapy (5-FU/LV, irinotecan, and temozolomide) plus bevacizumab in metastatic colon or rectal cancer. It focuses on tumors with an “MGMT silenced” pattern (MGMT gene turned off), which may make some cancers more responsive to these medicines.
Milan, MilanAges 18–75 - NCT05093907RecruitingPhase 1/Phase 2
Testing a new cancer drug plus capecitabine for metastatic colon cancer
This trial studies whether BEY1107, a new treatment, is safe and works better when combined with capecitabine in people with metastatic colorectal (colon/rectum) cancer. It is aimed at cancers that have already progressed after standard chemotherapy.
Seoul, Jongro-goAges 19 years+ - NCT05462613RecruitingPhase 2/Phase 3
Regorafenib plus aspirin then standard chemo for metastatic bowel cancer
This trial tests whether adding regorafenib and low-dose aspirin before standard chemotherapy can slow metastatic colorectal cancer after it has progressed on prior treatment. It may help by trying a different cancer-fighting approach earlier, followed by the usual chemo plan.
BesançonAges 18 years+
Hear when a new Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic cervical cancer?
- Yes. Clin2 currently lists 360 recruiting metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.